Abstract
Downregulation of Macrophage-Derived T-UCR uc.306 Associates with Poor Prognosis in Hepatocellular Carcinoma
a
Introduction
Hepatocellular carcinoma (HCC) is one of the most common cancers and the third leading cause of cancer-related death, with rising incidence worldwide [1, 2] . Although advances have been made in early diagnosis and treatment, especially in surgical techniques, the prognosis of HCC is still poor, with a median survival of 6-20 months. Less than 5% of the symptomatic patients survive for more than 2 years [3] [4] [5] [6] . According to the current guidelines, the curative therapies are mainly restricted to the early stage HCC patients [7] [8] [9] . Therefore, improvements in accurate detection of HCC at early stages, especially among high-risk groups such as cirrhosis or hepatitis patients, are more important in order to improve the treatment and prognosis of the patients [6, 10] . Studies have shown that the approach to improve diagnostic accuracy and help HCC patients to receive early therapeutic treatment [10, 11] .
Non-coding RNAs (ncRNAs) include microRNAs, long non-coding RNAs (lnc-RNA), and transcribed ultra-conserved RNAs (T-UCRs) [12, 13] . T-UCRs belong to the non-proteincoding DNA group and regulate the expression and translation of mRNAs that are strictly conserved across mice, rats, and humans [14] . Emerging evidence has shown that many T-UCRs act as oncogenes or tumor suppressor genes by post-transcriptionally regulating protein production [15, 16] . Macrophages are immune cells derived from embryonic precursors and circulating CD14 + monocytes that originate from the bone marrow [17] , activated macrophages) phenotypes [18] [19] [20] [21] . Increasing evidence has shown that M2 macrophages are capable of recruiting to the tumor site and increasing tumor angiogenesis [22, 23] . Studies have also shown that the number of tumor-associated macrophages (TAMs; mainly M2 phenotype) in tumor tissues is associated with poor patient prognosis [24, 25] , and tumor promotion [26] . Considering the essential roles of macrophages and T-UCRs in tumors, we measured the expression of T-UCRs in macrophages during the polarization from the M2 to the M1 phenotype. In this study, we detected the differential expression of T-UCRs in M1 and M2 macrophages using a microarray. The uc.306 was chosen because its possible target gene BTRC, which is overlapped with uc.306, may be involved in the Wnt signaling pathway that is closely linked to cancer development and metastasis. The expression of uc.306 in 30 paired HCC tissues and adjacent normal tissues was examined and the association of uc.306 and clinicopathological parameters and overall survival (OS) in investigating the expression and prognostic predictive role of uc.306 in HCC patients. This data may suggest novel markers for the diagnosis and treatment of HCC.
Materials and Methods
U937 cells were plated in 12-well plates and primed with fresh medium supplemented with different stimuli to obtain a gradient of polarity phenotypes. Phorbol 12-myristate 13-acetate (PMA) (100 ng/mL) was added into U937 cells cultured for 24 h, and then interleukin (IL)-4 (20 ng/mL) and IL13 (20 ng/ mL) were added to stimulate the differentiation of PMA-primed U937 cells to the M2 phenotype at 12 h post-incubation. Lipopolysaccharide (LPS) (100 ng/mL) and interferon (IFN)-gamma (20 ng/mL) were used to stimulate cell differentiation from the M2 to the M1 phenotype. The M1 and M2 phenotypes were synthase (iNOS) mRNAs. Replicate samples of polarized M1 and M2 cells were collected and stored at °C for subsequent microarray analyses. Fragmentation Buffer, then heating the mixture at Buffer was added to dilute the labeled cRNA. Fifty microliters of hybridization solution was dispensed into the gasket slide and assembled into the lncRNA expression microarray slide. The slides were incubated for 17 h at 65°C
LncRNA microarray and data analysis
Human T-UCRs are listed in website https://users.soe.ucsc.edu/~jill/ultra.html. Totally 482 human T-UCRs are included for now. For each T-UCR, basic information, such as length, region on chromosome gene, the online program RPISeq (http://pridb.gdcb.iastate.edu/RPISe) can be used. A value refer to the interaction intensity between T-UCR and its target gene is given, which helps to predict the interaction possibility between T-UCR and its target gene.
Patients and tissue specimens
September 2016. All 252 HCC patients were diagnosed by histopathological examination and the National Comprehensive Cancer Network (NCCN) clinical practice guidelines for oncology. All patients were followed up via telephone or hospital visit until death or at the last time of follow-up in 2016. The patients had a median follow up time of 17.3 months (range, 2-32 months). No patients had a previous cancer diagnosis at the initial screening examination. The clinicopathological characteristics of the patients including age, sex, pathological grades, bio-behavior of the cancer, serum alpha-fetoprotein (AFP) level, hepatic cirrhosis, and radical resection data were obtained from the medical records and pathological reports. The tumor status overall survival (OS), which was calculated from the date of pathological diagnosis/recruitment to death or the end of available follow-up data.
Immunohistochemistry (IHC)
3% H 2 O 2 at 37°C for 1 h and heated in 10 mM citrate buffer at 120°C for 2 min. The primary antibodies, CD68 (Abcam, Cambridge, UK; 1:200 diluted) and CD163 (Abcam; 1:100 diluted), were incubated at 4°C overnight, followed by incubation with a secondary peroxidase-conjugated antibody for 1 h at 37°C, and according to staining intensity. The intensity was scored as 0-3, with no staining (0), light yellow (1), pale brown (2), and dark brown (3) staining. The percentage of stained positive cells was scored 0-4, as the number of stained cells <5%, 5%-25%, 50%-75%, and >75%, respectively for the 0-4 scores. More than 1000 cells were counted on each slide and reviewed independently three times, by two pathologists who were blinded to the patients' clinical data. Positive or negative scoring was the product of the intensity score and the positive cell score (product less than 1 means negative, otherwise positive).
Total RNAs were isolated from cells using TRIzol ® reagent (Invitrogen Life Technologies, San Diego, CA, USA). One microgram of RNA was reverse-transcribed to cDNA using the PrimeScript First Strand cDNA synthesis kit (Takara Bio, Inc., Dalian, China) according to the manufacturer's instructions. The qRT-PCR was performed on an Applied Biosystems 7500 Real Time PCR system (Applied Biosystems, White Plains, conditions as follows: 40 cycles of 95°C for 5 min, 95°C for 10 sec, 58°C-60°C for 35 sec, followed by one primers are listed in Table 1 .
Statistical analysis
Statistical analyses were performed using SPSS, version 16.0 software (SPSS, Chicago, IL, USA). All three independent experiments were expressed as mean ± SD. Differences were assessed by two-tailed Student's t
Results
cells were pre-treated with PMA and stimulated with IL4 and IL13, to induce the M2 low expressions in M1 cells (Fig. 1A) . The M2 cells were polarized into the M1 phenotype by IL12 and iNOS mRNA in M1 cells, which showed low or zero expression in M2 cells (Fig. 1A) .
LncRNA microarray analysis
The U937 cells were stimulated to become M2 and M1 macrophages. Three duplicate samples of M1 and M2 cells were used to extract the total RNA. The Arraystar Human protein-coding transcripts, was used to analyze the expression of lncRNAs. A total of 26,276 lncRNAs were obtained and clustered in two phenotypes (M1 and M2) of U937 cells (Fig.  1B, C) . Further analyses showed that 2,977 lncRNAs belonging to T-UCRs were differentially expressed, among which 257 T-UCRs were differentially expressed (154 upregulated and 103 downregulated; q value <0.05; fold change >1.5) during the differentiation from the M2 to the M1 phenotype (Fig. 1C) . Six types of lncRNAs, the bidirectional, intergenic, intron sense-overlapping, exon sense-overlapping, intron antisense, and natural antisense, were found in the 257 T-UCRs (Fig. 1D) , of which the intergenic lncRNAs were the most abundant (62 upregulated T-UCRs and 70 downregulated T-UCRs), followed by the natural antisense, and exon sense-overlapping lncRNAs in both up-and downregulated T-UCRs.
The top ten up-and downregulated T-UCRs (picked up from the 257 T-UCRs), respectively, were grouped as shown in Fig. 2A , B, and showed that uc.306 had a higher normalized intensity in the M1 than in the M2 cells. We then analyzed the functions of the target genes of the top ten T-UCRs and found that these genes were involved in 18 biological processes, among which the "regulation of insulin secretion," "lipid metabolic processes," "signal transduction," "positive regulation of phagocytosis," and "neuromuscular process controlling" were the top with BTRC gene, which encode a beta-transducin repeat containing (BTRC) protein, namely -catenin (CTNNB1) , which is one of the key molecules in the Wnt pathway, and participates in three key pathways correlated to cancer regulation, including the Wnt signaling pathway, the Hippo signaling pathway, and the Hedgehog signaling pathway (Fig. 3B, C) . To further identify whether uc.306 interacts with was down-regulated (data not shown).
CD163
+ M2 macrophages were mainly found in HCC tissues, while high levels of CD68 + M1 macrophages were found in the adjacent normal tissues outcome of patients. In this study, we showed that uc.306 was highly upregulated in M1 cells, while it was downregulated in M2 U937cells. We therefore determined if the M2 and M1 phenotypes in our clinical samples had similar M2/M1 status as that of previous studies, by IHC using CD163 and CD68 as the indicators, respectively. The results showed that in 90 paired HCC tissues and corresponding adjacent normal tissues, the CD68 + macrophages (M1 phenotype) were mainly found in the adjacent normal tissues, which occupied 74.44% of the whole tissues. However, although the CD163 + macrophages (M2 phenotype) occupied a large proportion of the HCC tissues (84.44%), only a small number of adjacent normal tissues were CD163 positive (15.56%) (Fig. 4A) .
HCC patients
The expression levels of uc.306 in HCC tissues and their peritumor tissues were detected in 30 paired HCC patients, and the results showed that the levels of uc.306 in HCC tissues tissues (P < 0.0001) (Fig. 4B) . To validate these results, we then evaluated uc.306 expression expression was categorized into two groups depending on whether it was downregulated or upregulated when compared to the corresponding adjacent normal tissues. The results showed that the numbers of patients with lower levels of uc.306 were much greater than those with high level of uc.306 (Fig. 5A) , and the corresponding adjacent normal tissues usually had a higher expression of uc.306 compared to that of the HCC tissues (P < 0.0001, Fig. 5B ). To further examine the prognostic prediction role of uc.306 in HCC patients, KaplanMeier survival curves were used and the results showed that the expression of uc.306 was closely related to the OS of the patients (P = 0.0214, Fig. 5C ), and the lower expression of uc.306 predicted a worse prognosis when compared to the patients with higher expression OS compared to patients with high uc.306 levels.
Patient characteristics and clinical predictors
The impact of uc.306 expression on some clinicopathological features of HCC patients was analyzed and is shown in Table 2 . Overall, 36 female HCC patients and 216 male HCC patients were included, and the results showed that the sex, tumor size, number, lymph node the high and low uc.306 expression groups (Table 2 ). Univariate analyses indicated that age (HR = 2.42; 95%CI=1.23-4.76; P = 0.011), tumor capsule (HR = 1.93; 95% CI=1.16-3.2; P = 0.011), lymph node metastasis (HR = 3.050; 95% CI=1.59-5.86; P = 0.011), vascular invasion (HR = 3.38; 95% CI=2.02-5.64; P = 0.000), microvascular invasion (HR = 2.65; 95% CI=1.48-4.74; P = 0.001), BCLC stage (HR = 3.52; 95% CI=1.91-6.49; P = 0.000), and uc.306 expression (HR = 0.33; 95% CI=0.12-0.90: P = 0.030) were correlated with the OS of HCC patients, <5 cm), complete tumor capsule, no lymph node metastasis, no vascular invasion, no microvascular invasion, BCLC stage A, and higher uc.306 were associated with longer survival times ( Table 2 ). Multivariate analyses showed that age (HR = 0.39; 95% CI=0.16-0.98; P = 0.046), lymph node metastasis (HR = 2.51; 95% CI=1.30-4.87; P = 0.006), vascular invasion (HR = 3.51; 95% CI=2. 10-5.86 ; P = 0.000), and uc.306 expression (HR = 0.30; 95% CI=0.11-0.85; P = 0.023) contributed to the OS of HCC patients, showing similar trends with that of the univariate analyses (Table 3) .
Discussion
The numbers of macrophages involved in tumor angiogenesis, invasion, and metastasis correlated with the transformation from the M1 to the M2 phenotype, and the outcome was dependent on the status of M1 or M2 in cancer tissues or corresponding adjacent normal tissues. A greater number of M2 cells in tumor tissues correlated with a poorer outcome for the patients, while more M1 cells indicated a better prognosis [17, 21] . This was supported by our data showing that CD163 + M2 macrophages mainly were found in HCC tissues, while CD68 + M1 macrophages were highly expressed in the adjacent normal tissues. The results from the samples in our study supported the use of uc.306 that upregulated in M1 cells and downregulated in M2 cells for the prognosis of HCC patients. Because our microassay data showed uc.306 was higher in M1 cells, which was reported to be more recruited around cancer and detrimental to cancer development, but lower in M2 cells, which was reported -catenin (CTNNB1), one of the key molecules in the Wnt pathway. As known, the Wnt pathway is closely related to EMT supposed that there was a correlation between uc.306 expression and the phenotypic status regulates HCC metastasis is yet unclear.
for HCC [27] [28] [29] [30] [31] [32] . Specially, non-coding RNAs including microRNA and long non-coding RNA miR-361-5p could inhibit HCC growth and miR-335 would be associated with treatment response to trans-arterial chemoembolization and prognosis in HCC patients [33, 34] , and predicting diagnosis and diagnosis of HCC [35, 36] . Therefore, it is reasonable that T-UCRs (as one special type of lncRNAs) containing ultra-conserved elements have been reported to be potential biomarker for diagnosis and diagnosis of cancers. Moreover, T-UCRs could be altered in human carcinomas [14, 15] . For example, T-UCRs silencing was involved in addition, some T-UCRs (uc.63, uc.73,uc.206, uc.106, uc.134, and uc.475) could be regulated by hypoxia [39] , and could regulate cell proliferation and apoptosis [14] . Moreover, uc.63 overexpression was reported to correlate with poor prognosis in a luminal A subgroup of breast cancer patients [40] , and uc.73 levels indicated a positive correlation with overall survival [41] . These reports provided evidence that T-UCRs might play key roles in different aspects of cancer biology, as oncogenes or tumor suppressor genes. polarization of macrophages is still unknown and the role in tumor biology and prognosis remain unknown. In the present study, a total number of 2,977 T-UCRs were obtained during the polarization from the M2 to the M1 phenotype of U937 cells, with 1,061 downregulated genes and 1,916 upregulated genes. Furthermore, 257 T-UCRs had a fold change >1.5. During the polarization of M2 to M1 macrophages, the large numbers of differentially expressed T-UCRs suggested that T-UCRs might play very important roles. In the current study, the function of uc.306, one of the most upregulated T-UCRs in M1 phenotype macrophages, was shown to involve the Wnt signaling pathway, the Hippo signaling pathway, and the Hedgehog signaling pathway. These pathways have been implicated in HCC formation, growth, migration, metastasis, and epithelial-mesenchymal transition (EMT) [42] [43] [44] . Therefore, uc.306 may play a role in HCC development. Our results showed that uc.306 plays a role in HCC metastasis, because the overexpression of uc.306 suppressed the migration of SMMCAlthough the role of uc.306 in HCC remains unknown, its prognostic value for HCC patients should be studied. For this propose, the full length 640 bp uc.306 was obtained should be feasible. We found that uc.306 was expressed not only in all of the six HCC cell lines tissues, which was consistent with the microassay outcome showing uc.306 was expressed P = 0.045, fold change might have a positive correlation with HCC status. More importantly, the median survival was 17 months and 21 months in the low expression and high expression groups, respectively. P < 0.05), implying that uc.306 might be used as a biomarker for HCC.
Although the age, tumor size, tumor capsule, lymph node metastasis, vascular invasion, analyses, both univariate analyses and multivariate analyses showed that younger patients ( years), stronger lymph node metastasis, stronger vascular invasion, and lower uc.306 expression contributed to the poor OS of HCC patients. Among these risk factors, lymph node metastasis and vascular invasion were reported to be associated with HCC patient survival [45] [46] [47] , which was consistent with our observations. In our study, age was likely an independent risk factor, but the HR was small, which indicated that the patients >60 years of age might have better prognoses than the patients <60 years of age. Moreover, previous excluded age as a risk factor. Regarding uc.306, its HR was similar to that of age, therefore we were unsure if it was a risk factor. Although it was strongly suggested as a risk factor by both univariate analysis and multivariate analysis, the qPCR results on 252 HCC patients poor OS. Although our study demonstrated that uc.306 could be an independent prognostic biomarker of HCC, more studies, using a larger number of patients with longer follow-up times, and measuring the functions of uc.306 in different HCC cell lines, are needed to fully understand its function in proliferation, apoptosis, and HCC biology.
In conclusion, uc.306, expressed during macrophage polarization and expressed at
